Silo pharma expands development agreement with sever pharma for novel ketamine implant therapeutic

Sp-26 dissolvable ketamine-based injectable implant targets chronic pain and fibromyalgia sever pharma to scale-up extrusion processes and continue analytical testing for novel non-opioid treatment sarasota, fl, aug. 14, 2024 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced a new agreement with sever pharma solutions for scale-up extrusion of the company's sp-26 ketamine-loaded implant therapeutic targeting fibromyalgia and chronic pain. in addition, sever pharma solutions will continue with analytical testing of the ketamine hydrochloride (ketamine hcl) polymer implants using the optimal time-released, dose-controlled formulation previously selected by silo for continuing pre-clinical studies.
SILO Ratings Summary
SILO Quant Ranking